The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Contribution of p53 to Metastasis
Open accessAbstract
The tumor suppressor p53 is lost or mutated in about half of all human cancers, and in those tumors in which it is wild-type, mechanisms exist to prevent its activation. p53 loss not only prevents incipient tumor cells from undergoing oncogene-induced senescence and apoptosis, but also perturbs cell-cycle checkpoints. This enables p53-deficient tumor cells with DNA damage to continue cycling, creating a permissive environment for the acquisition of additional mutations. Theoretically, this could contribute to the evolution of a cancer genome that is conducive to metastasis. Importantly, p53 loss also results in the disruption of pathways that inhibit metastasis, and transcriptionally defective TP53 mutants are known to gain additional functions that promote metastasis. Here, we review the evidence supporting a role for p53 loss or mutation in tumor metastasis, with an emphasis on breast cancer. Significance: The metastatic potential of tumor cells can be positively influenced by loss of p53 or expression of p53 gain-of-function mutants. Understanding the mechanisms by which p53 loss and mutation promote tumor metastasis is crucial to understanding the biology of tumor progression and how to appropriately apply targeted therapies. Cancer Discov; 4(4); 405–14. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of the p53 mutant GOF has been reported to be associated with cellular physiopathology and poor clinical outcomes in cancer patients236–246 (Fig. 5).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [241]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
RetractedComprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links
Scheel, C., & Weinberg, R. A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.04.001 · Cited by 881
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression
Lin, T., Chao, C., Saito, S., Mazur, S. J., Murphy, M. E., Appella, E., & Xu, Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1211 · Cited by 859
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
Chang, C.-J., Chao, C.-H., Xia, W., Yang, J.-Y., Xiong, Y., Li, C.-W., Yu, W.-H., Rehman, S. K., Hsu, J. L., Lee, H.-H., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2173 · Cited by 745
Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1
McQuibban, G. A., Butler, G. S., Gong, J.-H., Bendall, L., Power, C., Clark-Lewis, I., & Overall, C. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107736200 · Cited by 655
miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions
Siemens, H., Jackstadt, R., Hünten, S., Kaller, M., Menssen, A., Götz, U., & Hermeking, H. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18552 · Cited by 609
P53 expression in breast cancer
Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., & Delia, D. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410204 · Cited by 601
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518
twist is a potential oncogene that inhibits apoptosis
Maestro, R., Tos, A. P. D., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D. H., & Hannon, G. J. (1999) · Genes & Development · doi:10.1101/gad.13.17.2207 · Cited by 516
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493
p53 and its mutants in tumor cell migration and invasion
Muller, P. A. J., Vousden, K. H., & Norman, J. C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009059 · Cited by 463
Godar, S., Ince, T. A., Bell, G. W., Feldser, D., Donaher, J. L., Bergh, J., Liu, A., Miu, K., Watnick, R. S., Reinhardt, F., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.006 · Cited by 456
p53 suppresses the self-renewal of adult neural stem cells
Meletis, K., Wirta, V., Hede, S.-M., Nistér, M., Lundeberg, J., & Frisén, J. (2006) · Development · doi:10.1242/dev.02208 · Cited by 413
Rosen, P. P., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1239 · Cited by 355
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Bian, J., & Sun, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6330 · Cited by 276
Stage-specific sensitivity to p53 restoration during lung cancer progression
Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Sanchez-Rivera, F. J., Resnick, R., Bronson, R., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 273
Nieto, M. A., & Cano, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.05.003 · Cited by 262
p53 regulates the expression of the tumor suppressor gene maspin
Zou, Z., Gao, C., Nagaich, A. K., Connell, T., Saito, S., Moul, J. W., Seth, P., Appella, E., & Srivastava, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6051 · Cited by 221
p53 in breast cancer subtypes and new insights into response to chemotherapy
Bertheau, P., Lehmann-Che, J., Varna, M., Dumay, A., Poirot, B., Porcher, R., Turpin, E., Plassa, L.-F., de Roquancourt, A., Bourstyn, E., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.07.005 · Cited by 215
The role of p53 in tumour suppression: lessons from mouse models
Attardi, L. D., & Jacks, T. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050269 · Cited by 201
Zhong, X., & Rescorla, F. J. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2011.10.005 · Cited by 180
Kodama, T., Takehara, T., Hikita, H., Shimizu, S., Shigekawa, M., Tsunematsu, H., Li, W., Miyagi, T., Hosui, A., Tatsumi, T., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44957 · Cited by 171
Gene expression patterns associated with p53 status in breast cancer
Troester, M. A., Herschkowitz, J. I., Oh, D. S., He, X., Hoadley, K. A., Barbier, C. S., & Perou, C. M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-276 · Cited by 168
Lark, A. L., Livasy, C. A., Dressler, L., Moore, D. T., Millikan, R. C., Geradts, J., Iacocca, M., Cowan, D., Little, D., Craven, R. J., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800424 · Cited by 167
KAI1/CD82, a tumor metastasis suppressor
Liu, W. M., & Zhang, X. A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.08.018 · Cited by 165
Kunz, C., Pebler, S., Otte, J., & von der Ahe, D. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.18.3710 · Cited by 160
SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis
Cheng, H., Liu, P., Wang, Z. C., Zou, L., Santiago, S., Garbitt, V., Gjoerup, O. V., Iglehart, J. D., Miron, A., Richardson, A. L., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000369 · Cited by 159
Recent Advances in the Therapeutic Perspectives of Nutlin-3
Secchiero, P., Bosco, R., Celeghini, C., & Zauli, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222586 · Cited by 158
The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53
Mashimo, T., Watabe, M., Hirota, S., Hosobe, S., Miura, K., Tegtmeyer, P., Rinker-Schaeffer, C. W., & Watabe, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11307 · Cited by 150
p53 Down-regulates Human Matrix Metalloproteinase-1 (Collagenase-1) Gene Expression
Sun, Y., Sun, Y., Wenger, L., Rutter, J. L., Brinckerhoff, C., & Cheung, H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11535 · Cited by 145
Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model.
Shi, H. Y., Zhang, W., Liang, R., Abraham, S., Kittrell, F. S., Medina, D., & Zhang, M. (2001) · PubMed · Cited by 129
Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility
Xia, M., & Land, H. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1208 · Cited by 127
Mehta, S., Christopherson, K. W., Bhat‐Nakshatri, P., Goulet, R. J., Broxmeyer, H. E., Kopelovich, L., & Nakshatri, H. (2006) · Oncogene · doi:10.1038/sj.onc.1210120 · Cited by 124
The p53 Tumor Suppressor Gene Inhibits Angiogenesis by Stimulating the Production of ThrombospondinPreprint
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.053 · Cited by 123
p53 regulates FAK expression in human tumor cells
Golubovskaya, V., Finch, R., Kweh, F. A., Massoll, N. A., Campbell‐Thompson, M., Wallace, M. R., & Cance, W. G. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20395 · Cited by 113
The Li-Fraumeni syndrome: An inherited susceptibility to cancer
Evans, S. C., & Lozano, G. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01105-2 · Cited by 101
Zhang, X. A., He, B., Zhou, B., & Liu, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303039200 · Cited by 95
Therapeutic targeting of p53 by small molecules
Selivanova, G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.006 · Cited by 93
Fidler, I. J., & Nicolson, G. L. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/58.6.1867 · Cited by 91
Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., & Rotter, V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4163 · Cited by 88
Crippling p53 activities via knock-in mutations in mouse models
Iwakuma, T., & Lozano, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210278 · Cited by 83
Mukhopadhyay, U. K., Eves, R. L., Jia, L., Mooney, P., & Mak, A. S. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01816-08 · Cited by 83
p53 modulation of anchorage independent growth and experimental metastasis.
Nikiforov, M. A., Hagen, K., Ossovskaya, V., Connor, T. M. F., Lowe, S. W., Deichman, G. I., & Gudkov, A. V. (1996) · PubMed · Cited by 79
Proteomic identification of the wt-p53-regulated tumor cell secretome
Khwaja, F. W., Svoboda, P., Reed, M. S., Pohl, J., Pyrzyńska, B., & Meir, E. G. V. (2006) · Oncogene · doi:10.1038/sj.onc.1209969 · Cited by 77
XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway
Tanikawa, C., Furukawa, Y., Yoshida, N., Arakawa, H., Nakamura, Y., & Matsuda, K. (2009) · Oncogene · doi:10.1038/onc.2009.154 · Cited by 68
Focal adhesion kinase and p53 signal transduction pathways in cancer
Vita, M. G. (2010) · Frontiers in bioscience · doi:10.2741/3653 · Cited by 67
Liu, J., Zhan, M., Hannay, J. A. F., Das, P. K., Bolshakov, S. V., Kotilingam, D., Yu, D., Lazar, A. F., Pollock, R. E., & Lev, D. C. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0201 · Cited by 61
Suad, O., Rozenberg, H., Brosh, R., Diskin-Posner, Y., Kessler, N., Shimon, L. J. W., Frolow, F., Liran, A., Rotter, V., & Shakked, Z. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.063 · Cited by 53
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53
Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50
Receptor protein tyrosine kinase DDR is up‐regulated by p53 protein
Sakuma, S., Saya, H., Tada, M., Nakao, M., Fujiwara, T., Roth, J. A., Sawamura, Y., Shinohe, Y., & Abe, H. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01234-3 · Cited by 39
Meyer, K. M., Hess, S. M., Tlsty, T. D., & Leadon, S. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202977 · Cited by 38
Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein.
Iotsova, V., & Stéhelin, D. (1996) · PubMed · Cited by 37
p53 mutations in matched primary and metastatic human tumors
PELLER, S., Halevy, A., SLUTZKI, S., Kopilova, Y., & Rotter, V. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130306 · Cited by 32
Özdemir, E., Kakehi, Y., Okuno, H., Habuchi, T., Okada, Y., & Yoshida, O. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00072 · Cited by 32
Vitale, M., Matola, T. D., Bifulco, M., Casamassima, A., Fenzi, G., & Rossi, G. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01512-4 · Cited by 31
Research works printed but not linked: 5
- Brummer, 1999, Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study, Virchows Arch, 435, 566, 10.1007/s004280050442 · doi:10.1007/s004280050442
- Remacle, 1998, Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer, Br J Cancer, 77, 926, 10.1038/bjc.1998.153 · doi:10.1038/bjc.1998.153
- Liotta, 1978, In vivo monitoring of the death rate of artificial murine pulmonary micrometastases, Cancer Res, 38, 1231
- Varani, 1980, In vitro and in vivo adherence of tumor cell variants correlated with tumor formation, Am J Pathol, 101, 345
- Parker, 2000, Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines, Ann Clin Lab Sci, 30, 395
Cited by
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Apoptosis, autophagy, necroptosis, and cancer metastasis
Su, Z., Yang, Z., Xu, Y., Chen, Y., & Yu, Q. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0321-5 · Cited by 1,042
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Metadata
- Authors
- Powell, E., Piwnica-Worms, D., & Piwnica-Worms, H.
- Venue
- Cancer Discovery
- Published
- 2014-04-01
- Volume
- 4
- Issue
- 4
- Pages
- 405-414
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4063123
- OpenAlex
- W2169385603
- Cited by
- 355
- References
- 75
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.